Markets

Testosterone replacement biotech Clarus Therapeutics withdraws $86 million IPO

Clarus Therapeutics, a biotech awaiting FDA approval for an oral testosterone replacement therapy, withdrew its plans for a planned $86 million initial public offering on Wednesday. The Northbrook, IL-based company was founded in 2003 and previously withdrew an IPO filing in July 2011. Citi and Credit Suisse were set to be the joint bookrunners on the deal.

The article Testosterone replacement biotech Clarus Therapeutics withdraws $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More